NEXGEL, Inc. Share Price

NXGL

US65344E2063

Pharmaceuticals

Market Closed - Nasdaq 20:00:00 27/10/2026 GMT			5-day change	1st Jan Change
4.255 ^USD	+7.45%		-26.64%	-86.79%

09-24	NEXGEL, Inc. - Special Call
08-24	Maxim Downgrades NexGel to Hold From Buy	MT

Last Transcript: NEXGEL, Inc.

NEXGEL, Inc. - Special Call

09-24

More transcripts

Analysts' recommendations: NEXGEL, Inc.

08-24

Maxim Downgrades NexGel to Hold From Buy

More recommendations

Managers and Directors: NEXGEL, Inc.

Manager	Title	Age	Since
Brian Kieser CEO	Chief Executive Officer	59	20/08/2026
Ian Blackman DFI	Director of Finance/CFO	58	26/04/2026
Gregory J. Robb COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Jerome Zeldis BRD	Director/Board Member	76	31/03/2020
Steven Glassman CHM	Chairman	61	-
Steven Ciardiello BRD	Director/Board Member	55	30/07/2025

More insiders

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Companyâ€™s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
27/10/26	US$4.255	+7.45%	17,649
26/10/26	US$3.960	-21.27%	48,513
23/10/26	US$5.030	+5.67%	54,363
22/10/26	US$4.760	-9.85%	31,673
21/10/26	US$5.280	-0.94%	54,212

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.255

Average target price

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - NEXGEL, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - NEXGEL, Inc.

Company calendar

Market Cap	2.07M 1.86M 1.72M 1.56M 2.91M 197M 2.95M 20.63M 8.19M 103M 7.78M 7.62M 328M	P/E 2026 *	-0.23x	P/E 2027 *	-0.97x
Enterprise Value	2.07M 1.86M 1.72M 1.56M 2.91M 197M 2.95M 20.63M 8.19M 103M 7.78M 7.62M 328M	EV / Sales 2026 *	0.13x	EV / Sales 2027 *	0.09x
Free-Float	85.98%	Yield 2026 *	-	Yield 2027 *	-

09-24	NEXGEL, Inc. - Special Call
08-24	Maxim Downgrades NexGel to Hold From Buy	MT
08-20	Nexgel, Inc. Forms Special Committee to Oversee Comprehensive Strategic Review and Value Creation	CI
08-20	Nexgel, Inc. Announces CEO Changes, Effective August 21, 2026	CI
08-20	Nexgel, Inc. Announces Special Committee, Effective August 21, 2026	CI
08-20	NexGel Files to Register 15.25 Million Shares From Note Conversions	MT
08-17	NEXGEL, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-02	Nexgel, Inc. Announces Resignation of Scott Henry as Member of Board of Directors, Effective July 1, 2026	CI
05-19	NEXGEL, Inc. Reports Positive Data From Randomized Single-Center IRB Study To Evaluate The Effectiveness And Safety Of A Hydrogel Laser Treatment Patch In Laser Hair Removal	CI
05-15	NEXGEL, Inc., Q1 2026 Earnings Call, May 15, 2026
05-14	NEXGEL, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	NEXGEL, Inc. announced that it has received $1.21 million in funding	CI
05-13	Nexgel appoints Dave Hazard as vice president of sales for Bionx Surgical	RE

09-23	NEXGEL Announces Dial-In Details for Investor Update Call	AQ
09-16	NEXGEL Announces Date for Investor Update Call	AQ
08-20	NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE	AQ
08-17	NEXGEL Reports Second Quarter 2026 Financial Results	AQ
06-05	NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th -18th	AQ

1 day	+7.45%
1 week	-26.64%
Current month	+23.12%
1 month	+22.27%
3 months	-51.54%
6 months	-67.07%
Current year	-86.79%

1 week	3.61	5.5
1 month	3	7.25
Current year	3	38
1 year	3	53.6
3 years	3	102
5 years	3	102
10 years	3	102

NEXGEL, Inc. Share Price

Stocks

NXGL

US65344E2063

Pharmaceuticals

Valuation: NEXGEL, Inc.

Chart: NEXGEL, Inc.

Latest news: NEXGEL, Inc.

Last Transcript: NEXGEL, Inc.

Analysts' recommendations: NEXGEL, Inc.

Press Releases: NEXGEL, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: NEXGEL, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/07/26	Adam Levy	Free	Chief Executive Officer	160,000	1.7344%
08/06/26	Adam Levy	Sell	Chief Executive Officer	-3,000	0.0329%
01/06/26	Adam Levy	Sell	Chief Executive Officer	-2,000	0.0219%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEXGEL, INC.	+7.45%	-26.64%	-91.79%	-86.09%	1.93M
ELI LILLY AND COMPANY	+0.22%	+3.35%	+55.30%	+125.65%	1,140B
JOHNSON & JOHNSON	+0.91%	+5.89%	+41.14%	+80.36%	641B
ABBVIE INC.	-0.12%	+1.31%	+25.62%	+97.24%	507B
ROCHE HOLDING AG	+0.63%	+4.97%	+47.12%	+68.18%	383B
MERCK & CO., INC.	+0.86%	-1.26%	+62.10%	+34.36%	347B
NOVARTIS AG	+1.02%	+3.69%	+23.73%	+51.35%	293B
ASTRAZENECA PLC	-0.25%	+3.40%	+2.31%	+23.38%	266B
AMGEN INC.	+0.75%	+5.41%	+53.53%	+66.09%	240B
GILEAD SCIENCES, INC.	+0.25%	+3.93%	+31.54%	+102.65%	197B
Average	+0.88%	-0.54%	+25.06%	+56.32%	401.38B
Weighted average by Cap.	+0.02%	+2.98%	+42.01%	+84.56%

	2026 *	2027 *
Net sales	15.79M 14.18M 13.09M 11.86M 22.18M 1.5B 22.46M 157M 62.38M 787M 59.25M 57.98M 2.49B	24.27M 21.8M 20.11M 18.24M 34.09M 2.31B 34.53M 241M 95.89M 1.21B 91.08M 89.13M 3.83B
Net income	-8.33M -7.48M -6.9M -6.26M -11.7M -792M -11.85M -82.83M -32.9M -415M -31.25M -30.58M -1.32B	-2.31M -2.08M -1.92M -1.74M -3.25M -220M -3.29M -23M -9.14M -115M -8.68M -8.49M -365M
Net Debt	-	-

Markets		Quality
Nasdaq	NXGL	Delayed
CBOE	NXGL	Real-time